Global Summit Reviews Advances and Opportunities for Strategic Collaborations to Speed Pathways to MS Cures
Pathways to Cures Global Summit I (Stuart Schlossman) was fortunate to have been asked, and to have attended this Global…
Tolebrutinib safely lowers relapse rates over 2.5 years
Phase 2b extension trial now has 125 MS patients on 60 mg daily dose About 2.5 years of treatment with tolebrutinib was…
Stuart Schlossman
EBV-Autoimmune disease treatment that could expand overall MS treatment program options
Created on Sunday, 26 March 2023 14:33 by Alan M Dattner, MD doctordattner@gmail.com I was excited to see the studies…
Stuart Schlossman
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study…
Stuart Schlossman
Primary progressive MS confirmed as own disorder in mouse study
Antibodies in spinal fluid seen to drive PPMS, but not relapsing MS by Marisa Wexler, MS | February 7, 2023…
Stuart Schlossman
More Inflammation Biomarkers in Spinal Fluid of PPMS Patients: Study
Biomarkers show weak correlation with PPMS activity and severity by Patricia Valerio, PhD | November 25, 2022 Individuals with primary progressive multiple sclerosis (PPMS) have…
Stuart Schlossman
Remyelination, CNM-Au8, diet and bones
More remyelination research For years, most MS research has focused on stopping disease progression. In the past couple years,…
Stuart Schlossman
Similar Processes Could Link MS With Heart Disease
By Cara Murez HealthDay Reporter WEDNESDAY, March 22, 2023 — Multiple sclerosis (MS) and atherosclerosis both involve an abnormal hardening of body tissue, and…
Stuart Schlossman
Astrocyte receptors may help to ease MS cognitive issues – presented at ACTRIMS 2023
by Lindsey Shapiro, PhD | February 28, 2023 MS mouse models genetically engineered to lack these receptors, called TNFR2, showed…
Stuart Schlossman
Octave Presents Data from Nine Company and Partner Abstracts at ACTRIMS Forum 2023 on MSDA and more
Real-world data sets show components of value-based care, use of Octave’s Multiple Sclerosis Disease Activity test and deep scan biomarker…
Stuart Schlossman
